CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Testosterone +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01725451
NCT01725451Phase 1Completed
CompareCT.gov

Effects of Deodorant and Antiperspirant Use and the Presence of Axillary Hair on the Absorption of Testosterone Applied as Testosterone 2% Solution

Eli Lilly and Company·interventional·Posted Nov 12, 2012·Updated Oct 16, 2014

In Brief

A Phase 1 clinical trial evaluating Testosterone, Deodorant Spray, and 2 other interventions for Healthy Participants. Completed, enrolled 30 participants across 2 sites.

Detailed Summary

This study will evaluate the effect of deodorant and antiperspirant use and the presence of underarm hair on the absorption of testosterone. Each participant in this study will receive 6 single doses of 30 milligrams (mg) testosterone applied as a solution to each underarm. There is a minimum one day washout period between each dose. This study will last approximately 24 days not including screening. Screening is required within 30 days prior to the start of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 12, 2012
Enrollment StartNov 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.6 years ago

Interventions

Testosteronedrug

Administered topically to axillae

Deodorant Sprayother

Administered topically to axillae

Deodorant and Antiperspirant Combination Sprayother

Administered topically to axillae

Deodorant and Antiperspirant Combination Stickother

Administered topically to axillae